Work

Finerenone in heart failure with left ventricular ejection fraction ≥40%: a correspondence

Year: 2025

Type: article

Abstract: Finerenone, the first nonsteroidal mineralocorticoid receptor antagonist approved by the U.S. Food and Drug Administration for treating heart failure (HF) with mildly reduced ejection fraction and HF with preserved ejection fraction reduces morbidity and mortality by mitigating inflammation and fibrosis. The FINEARTS-HF (Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction) trial demonstrated significant benefits, particularly after recent HF events, with ongoing studies evaluating broader applications across the cardio-kidney-metabolic spectrum.

Source: Annals of Medicine and Surgery

DOI: 10.1097/ms9.0000000000003995

Authors: Muhammad Furqan, Muhammad Usman Haider, Sadia Binte Rahim

Institutions: King Edward Medical University, Geisinger Health System, Mymensingh Medical College Hospital

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,850